Quay Pharmaceuticals Sets Up Headquarters in Wales
North Wales - November 10, 2009
Quay Pharmaceuticals is investing £2.7million in a new headquarters and manufacturing facility in North Wales where, with support from the Welsh Assembly Government, it will create 54 new high quality jobs. Operations at the new site will include early stage research & development and clinical trials manufacturing for the global pharmaceutical and biotechnology industries.
Quay Pharma is a welcome addition to the healthcare and bioscience sector in Wales which employs some 15,000 people and is worth around £1.3billion annually to the Welsh economy. Support was provided through the Single Investment Fund to facilitate the company’s expansion programme, said Ieuan Wyn Jones, Minister for the Economy and Transport.
“Quay Pharma will be creating a range of high quality jobs over the next few years providing excellent employment opportunities for Welsh graduates,” said Wyn Jones.
The range of support offered by the Assembly Government to small and medium sized businesses had made Wales an attractive proposition for Quay Pharma’s expansion, Chief Executive Officer Mike Rubinstein said.
“The support from the Assembly Government is great for a small company and of particular help in the current economic climate. Not only does it provide advice and access to knowledge but also provides businesses with a high level of promotional and marketing support at overseas events," Rubenstein said.
The company is currently fitting out laboratories and offices with the aim of opening in January. The manufacturing operation is due to relocate during the first quarter of next year.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
